Enterprise Value
113.8M
Cash
241.7M
Avg Qtr Burn
-10.52M
Short % of Float
9.42%
Insider Ownership
2.69%
Institutional Own.
93.19%
Qtr Updated
03/31/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
ZYNYZ (Retifanlimab) (anti-PD-1 mAb) Details Solid tumor/s, Cancer, Metastatic merkel cell carcinoma, Skin cancer | Approved Quarterly sales | |
MARGENZA (Margetuximab) (Fc-engineered, anti-HER2 mAb) Details HER2-positive metastatic breast cancer | Approved Quarterly sales | |
Retifanlimab (anti-PD-1 mAb) Details NSCLC (Non-small cell lung carcinoma) or Anal Cancer | NDA FDA meeting | |
Vobramitamab duocarmazine (vobra duo) (MGC018) Details Solid tumor/s, Cancer, Castration-resistant prostate cancer | Phase 2 Data readout | |
Enoblituzumab (anti-B7-H3) Details Head and neck squamous cell carcinoma, Cancer | Phase 2 Update | |
Lorigerlimab (PD-1 × CTLA-4 bispecific DART® molecule) + docetaxel Details Solid tumor/s, Cancer, Castration-resistant prostate cancer | Phase 2 Initiation | |
Vobramitamab duocarmazine combo w/lorigerlimab (PD-1 × CTLA-4 bispecific DART® molecule) Details Solid tumor/s, Non-small cell lung carcinoma, Cancer, Triple-negative breast cancer , Head and neck squamous cell carcinoma, Melanoma, Castration-resistant prostate cancer | Phase 1 Data readout | |
MGD024 Details Myelodysplastic syndrome, Acute myeloid leukemia | Phase 1 Data readout | |
Margetuximab (Fc-engineered, anti-HER2 mAb) Details Gastric cancer, Cancer | Failed Discontinued | |
Flotetuzumab (bispecific CD123 × CD3 DART molecule) Details Cancer, Multiple myeloma, Acute myeloid leukemia | Failed Discontinued |